The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review
Chemotherapy-induced peripheral neuropathy is a common adverse effect occurring in patients undergoing neurotoxic chemotherapy. However, there is no FDA-approved treatment option for it. Given the importance of clinical practice guidelines in this area, this study aimed to determine the methodologic...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/359 |
| _version_ | 1828073759523733504 |
|---|---|
| author | Shahin Salarvand Simin Hemati Payman Adibi Fariba Taleghani |
| author_facet | Shahin Salarvand Simin Hemati Payman Adibi Fariba Taleghani |
| author_sort | Shahin Salarvand |
| collection | DOAJ |
| description | Chemotherapy-induced peripheral neuropathy is a common adverse effect occurring in patients undergoing neurotoxic chemotherapy. However, there is no FDA-approved treatment option for it. Given the importance of clinical practice guidelines in this area, this study aimed to determine the methodological quality of extant CIPN guidelines. The study was done as part of the adaptation process of CIPN related CPGs at Isfahan University of Medical Sciences, Iran. A systematic search of published CPGs about chemotherapy-induced CIPN in which the AGREE II instrument was applied for appraising CPGs of CIPN was performed. In general, amongst all of the AGREE II Instrument’s domains in the evaluated CPGs, the clarity of presentation and stakeholder involvement domains took favorable scores; and other domains obtained unfavorable and relatively favorable scores. The quality of cancer therapy-induced neuropathy CPGs needs to be improved and designing high-quality CPGs must be considered. |
| first_indexed | 2024-04-11T01:34:20Z |
| format | Article |
| id | doaj.art-10b2af661bfc4e0288ad59fb76b28e8a |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:34:20Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-10b2af661bfc4e0288ad59fb76b28e8a2023-01-03T08:58:34ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652018-10-0112210.4081/oncol.2018.359The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A reviewShahin Salarvand0Simin Hemati1Payman Adibi2Fariba Taleghani3Social Determinant Health Research Center, Faculty of Nursing and Midwifery, Lorestan University of Medical Sciences, KhorramabadRadiation oncology department, Faculty of Medicine, Isfahan University of Medical Sciences, IsfahanIntegrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, IsfahanNursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, IsfahanChemotherapy-induced peripheral neuropathy is a common adverse effect occurring in patients undergoing neurotoxic chemotherapy. However, there is no FDA-approved treatment option for it. Given the importance of clinical practice guidelines in this area, this study aimed to determine the methodological quality of extant CIPN guidelines. The study was done as part of the adaptation process of CIPN related CPGs at Isfahan University of Medical Sciences, Iran. A systematic search of published CPGs about chemotherapy-induced CIPN in which the AGREE II instrument was applied for appraising CPGs of CIPN was performed. In general, amongst all of the AGREE II Instrument’s domains in the evaluated CPGs, the clarity of presentation and stakeholder involvement domains took favorable scores; and other domains obtained unfavorable and relatively favorable scores. The quality of cancer therapy-induced neuropathy CPGs needs to be improved and designing high-quality CPGs must be considered.https://www.oncologyreviews.org/index.php/or/article/view/359Appraisingqualityclinical guidelinesperipheral neuropathy. |
| spellingShingle | Shahin Salarvand Simin Hemati Payman Adibi Fariba Taleghani The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review Oncology Reviews Appraising quality clinical guidelines peripheral neuropathy. |
| title | The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review |
| title_full | The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review |
| title_fullStr | The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review |
| title_full_unstemmed | The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review |
| title_short | The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review |
| title_sort | quality of guidelines in non pharmacological prevention and management of chemotherapy induced neuropathy a review |
| topic | Appraising quality clinical guidelines peripheral neuropathy. |
| url | https://www.oncologyreviews.org/index.php/or/article/view/359 |
| work_keys_str_mv | AT shahinsalarvand thequalityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT siminhemati thequalityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT paymanadibi thequalityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT faribataleghani thequalityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT shahinsalarvand qualityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT siminhemati qualityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT paymanadibi qualityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview AT faribataleghani qualityofguidelinesinnonpharmacologicalpreventionandmanagementofchemotherapyinducedneuropathyareview |